References
- Motoo Y, Sawabu N, Minamoto T, Kawakami H, Ohta H, Okai T, et al. Rapid growing mucinous cholangiocarcinoma. Int Med 1993;32:116–21.
- Chamberlain RS, Blumgart LH. Mucobilia in association with a biliary cystadenocarcinoma of the caudate duct: a rare cause of malignant biliary obstruction. HPB Surgery 2000; 11:345–51.
- Kokubo T, Itai Y, Ohtomo K, Itoh K, Kawauchi N, Minami M. Mucin-hypersecreting intrahepatic biliary neoplasms. Radiology 1988;168:609–14.
- Chen MF, Jan YY, Chen TC. Clinical studies of mucinproducing cholangiocellular carcinoma. Ann Surg 1998;1:63–9.
- Chou ST, Chan CW. Mucin-producing cholangiocarcinoma: an autopsy study in Hong Kong. Pathology 1976;8:321–8.
- Kenjo A, Abe T, Saito T, Tsuchiya T, Yamada F, Kanzaki N, et al. Mucin ball-producing extrahepatic bile duct carcinoma. Scand J Gastroenterol 2000;35:1330–4.
- Sakamoto E, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, et al. Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma: value of percutaneous transhepatic biliary drainage and cholangioscopy. World J Surg 1999;23:1038–44.
- Jan YY, Chen MF, Hung CF. Cholangiography of mucinhypersecreting intrahepatic biliary neoplasms. J Hep Bil Pancr Surg 1997;4:180–4.
- Nakajima T, Kondo Y, Miyazaki M. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol 1988; 19:1228–34.
- Lin HH, Wang LY, Hu CT, Huang SC, Huang LC, Lin SS, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003;69:471–4.
- Lin CC, Hwang SJ, Chiou ST, Kuan CL, Chen LW, Lee TC, et al. The prevalence and risk factors analysis of serum antibody to hepatitis C virus in the elderly in northeast Taiwan. J Chin Med Assoc 2003;66:103–8.
- Jan YY, Chen MF, Chen TJ. Cholangiocarcinoma with mucobilia. J Formos Med Assoc 1994;93:149–55.
- Su WC, Chan KK, Lin XZ, Lin PW, Chow NH, Shin JS, et al. A clinical study of 130 patients with biliary tract cancers and periampullary tumors. Oncology 1996;53:488–93.
- De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368–78.
- Bjornsson E, Kilander A, Olsson R. CA19–9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999;19: 501–8.
- Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865–9.
- Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, et al. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepato-Gastroenterology 2002;49:740–5.
- Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA19–9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95: 204–7.